Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer
Phase II Trial of Transdermal Estradiol in Patients With Hormone Refractory Prostate Cancer
Sponsor: National Cancer Institute (NCI)
Terminated
Treatment ineffective
Other terminated trials from National Cancer Institute (NCI)
Other Prostate Cancer trials with similar outcome
A PHASE2 clinical study on Prostate Cancer, this trial is terminated or withdrawn. The trial is conducted by National Cancer Institute (NCI) and has accumulated 7 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Oct 2023 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
May 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- University of Medicine and Dentistry of New Jersey
For direct contact, visit the study record on ClinicalTrials.gov .